Clinical Trial

EP102 Safety and Efficacy in METTL3 Modulation in Advanced Solid Tumors

Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
This the first-in-human (FIH) study for the Investigational Medicinal Product (IMP) EP102, is designed to explore the maximum tolerated dose (MTD), the overall safety profile, its pharmacokinetic (PK) / pharmacodynamic (PD) profile, and an exploratory evaluation of antitumor activity in participants with advanced solid tumors, who have no available standard therapy or who have failed standard therapies. This study will inform on recommended doses for further studies, e.g. dose optimization studies and / or efficacy and safety studies.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-09-01.
Trial Details
NCT Number NCT07163325
Lead Sponsor Epics Therapeutics
Conditions Advanced Solid Tumor (Phase 1)
Enrollment 48 participants
Start Date 2025-07-24
Primary Completion 2027-11 (estimated)
Study Completion 2028-11 (estimated)
Updated on ClinicalTrials.gov 2026-06-11